Absolute Bioavailability and ADME study of Savolitinib in Healthy Male Subjects

Study identifier:D5084C00010

ClinicalTrials.gov identifier:NCT04675021

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I Open-label Study to Assess the Absolute Bioavailability of Savolitinib and Absorption, Distribution, Metabolism, Excretion of [14C]Savolitinib in Healthy Male Subjects

Medical condition

cancer

Phase

Phase 1

Healthy volunteers

Yes

Study drug

-

Sex

Male

Actual enrollment

8

Study type

Interventional

Age

30 Years - 65 Years

Date

Study Start Date: 13 Nov 2020
Primary Completion Date: 11 Jan 2021
Study Completion Date: 11 Jan 2021

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Quotient Sciences Limited

Inclusion and exclusion criteria